Tibet Pharmaceutical H1 2026 Revenue Slides 5.83%, Net Profit Rises 7.16%, Plans Dividend
Tibet Pharmaceutical's first-half 2026 operating revenue fell 5.83% year-on-year to RMB 1.554 billion, while net profit attributable to shareholders climbed 7.16% to RMB 608 million. Basic earnings per share totaled RMB 1.91. The company proposed a cash dividend of RMB 11.46 per 10 shares (including tax). During the period, industrial support funds received increased by RMB 155 million versus the same 2025 period.
Tibet Pharmaceutical disclosed its interim report for the first half of 2026. The report shows that the company achieved operating revenue of RMB 1.554 billion in the first half, down 5.83% year-on-year; net profit attributable to shareholders of the listed company was RMB 608 million, up 7.16% year-on-year; and basic earnings per share were RMB 1.91.
The company also announced a profit distribution plan, proposing to distribute a cash dividend of RMB 11.46 (including tax) per 10 shares to all shareholders. During the reporting period, the industrial support funds received by the company increased by RMB 155 million compared with the same period of 2025.